Get the Stockscreener App
1.53
0.00%
0.00
Taysha Gene Therapies Inc stock is traded at $1.53, with a volume of 1.80M.
It is up +0.00% in the last 24 hours and down -17.30% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$1.53
Open:
$1.53
24h Volume:
1.80M
Relative Volume:
0.46
Market Cap:
$313.56M
Revenue:
$12.87M
Net Income/Loss:
$-114.34M
P/E Ratio:
-1.7696
EPS:
-0.8646
Net Cash Flow:
$-79.23M
1W Performance:
-5.56%
1M Performance:
-17.30%
6M Performance:
-28.50%
1Y Performance:
+6.25%
1-Day Range:
$1.47
$1.585
1-Week Range:
$1.47
$1.75
52-Week Range:
$1.19
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
1.53 | 313.56M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) PT at $6.63 - MarketBeat
Barclays PLC Increases Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Barclays PLC Boosts Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
JPMorgan Chase & Co. Boosts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Jane Street Group LLC Sells 20,552 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Principal Financial Group Inc. Sells 5,810 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Given “Buy” Rating at Needham & Company LLC - Defense World
Assessing Taysha Gene Therapies: Insights From 8 Financial Analysts - Benzinga
Taysha Gene Therapies' (TSHA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Grants 311,000 Stock Options to New Employee Under Inducement Plan - StockTitan
100,795 Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Bought by Franklin Resources Inc. - Defense World
Barclays PLC Buys 193,046 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Geode Capital Management LLC Acquires 682,273 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Geode Capital Management LLC Buys 682,273 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest Update - MarketBeat
State Street Corp Has $6.97 Million Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Wellington Management Group LLP Buys New Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
The Manufacturers Life Insurance Company Sells 72,548 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies' SWOT analysis: promising rett syndrome stock faces key tests - Investing.com Canada
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Fmr LLC Has $37.54 Million Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by Fmr LLC - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 6.3%Still a Buy? - MarketBeat
Taysha Gene Therapies Issues 152,000-Share Stock Option Grant to New Executive Hire - StockTitan
Canadian Imperial Bank of Commerce (CM-N) QuotePress Release - The Globe and Mail
RTW Investments LP Sells 3,853,879 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Rett Syndrome Market Forecast: Key Drivers and Opportunities - openPR
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Brokerages - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.3%Time to Buy? - MarketBeat
Acuta Capital Partners LLC Cuts Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
TSHA (Taysha Gene Therapies) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
TSHA (Taysha Gene Therapies) EPS without NRI : $-0.29 (TTM As of Sep. 2024) - GuruFocus.com
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
Taysha Gene Therapies' SWOT analysis: stock poised for growth in Rett syndrome market - Investing.com
TSHA (Taysha Gene Therapies) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Amgen (NASDAQ:AMGN) vs. Taysha Gene Therapies (NASDAQ:TSHA) Head-To-Head Comparison - Defense World
TSHA (Taysha Gene Therapies) 5-Day RSI : 71.01 (As of Nov. 24, 2024) - GuruFocus.com
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 13.8%Here's What Happened - MarketBeat
GSA Capital Partners LLP Raises Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Recent Analysts’ Ratings Updates for Taysha Gene Therapies (TSHA) - Defense World
Canaccord Genuity Group Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Neurogene rethinks gene therapy trial after high dose leaves Rett patient in critical condition - Fierce Biotech
Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts - Benzinga
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2024 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):